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ABSTRACT
Objective: At present, the coronavirus disease (COVID)-19 pandemic is increasing global health concerns. This coronavirus outbreak is caused by 
severe acute respiratory syndrome coronavirus (SARS-CoV)-2. Since, no specific antiviral for treatment against COVID-19, so identification of new 
therapeutics is an urgent need. The objective of this study is to the analysis of lichen compounds against main protease and spike protein targets of 
SARS-CoV-2 using in silico approach.
Methods: A total of 108 lichen compounds were subjected to ADMET analysis and 14 compounds were selected based on the ADMET properties and 
Lipinski’s rule of five. Molecular docking was performed for screening of selected individual lichen metabolites against the main protease and spike 
proteins of SARS-CoV-2 by Schrodinger Glide module software.
Results: Among the lead compounds, fallacinol showed the highest binding energy value of −11.83 kcal/mol against spike protein, 4-O-Demethylbarbatic 
acid exhibited the highest dock score of −11.67 kcal/mol against main protease.
Conclusion: This study finding suggests that lichen substances may be potential inhibitors of SARS-CoV-2.
Keywords: Coronavirus disease-19, Severe acute respiratory syndrome coronavirus-2, Docking, Lichen Compounds, Main protease, Spike protein.
INTRODUCTION
Coronavirus disease (COVID-19) was emerged from Wuhan city, 
China, in December 2019 as an epidemic, this disease mainly targets 
the human respiratory system [1,2]. According to the World Health 
Organization, 202,608,306 confirmed cases and 4,293,591 deaths were 
reported globally as of August 9, 2021 [3]. This virus mainly spread 
through droplets produced from sneezing, coughing, talking, and close 
contact with the infected person [4,5]. COVID-19 patients are treated 
using symptomatic therapy due to the unavailability of approved 
specific drugs [6]. Hence, there is an urgent need to discover drugs for 
the clinical management of COVID-19.
Severe acute respiratory syndrome coronavirus (SARS-CoV)-2 contains 
positive-sense single-stranded RNA (+ssRNA) as genetic material and 
this virus produces nearly 800 KD polypeptides. These polypeptides 
encode main protease (Mpro) and RNA-dependent RNA polymerase 
(RdRp), spike protein (S protein) other structural proteins [7,8]. 
Main protease is an essential enzyme for viral replication, involved 
in cleaving polypeptides and mediating replication and transcription. 
Hence, main protease (Mpro) is one of the key targets to stop viral 
replication. Spike protein (S protein) is a surface protein that helps 
for virus attachment with angiotensin-converting enzyme 2 (ACE 2) 
receptors. Thus, spike (S) protein is considered as one of the main 
target for COVID-19 therapeutics [9].
Lichens are a symbiotic association of fungi and algae; occur in a 
variety of habitats and natural environmental conditions. Lichen 
metabolites were reported to exhibit intense analgesic, antipyretic [10], 
anti-inflammatory [11], antimicrobial [12], antiviral [13], and cytotoxic 
activities [14]. The current scenario of molecular docking and 
computational studies opens new possibilities of drug screening and 
may assist in the development of COVID-19 treatment [15].
The aim of the present study was made to screening the lichen 
substances to identifying the potential drug to inhibit SARS-CoV-2 main 
protease and spike protein by molecular docking method.
METHODS
Accession of target protein
The COVID-19 main protease (Mpro) and spike proteins (S protein) were 
selected as target proteins. The X-ray crystal structure of the above 
proteins was retrieved from the Protein Data Bank database (PDB ID: 
6lu7 and 6M0J) for this virtual screening study [https://www.rcsb.org/
pdb/home/home.do].
Ligand selection
A total of 108 lichen metabolites were selected and retrieved that the 
compounds were from the PubChem database as SDF format and it 
was subsequently converted into PDB format using Open Babel free 
software. The retrieved structure energy was minimized and hydrogen 
atoms were added and charges were assigned using Gasteiger.
ADME prediction
The ADME (Adsorption, Distribution, Metabolism, and Excretion) 
properties were analyzed for the compounds to test its drug-likeness 
using QikProp, a Schrodinger module. The ADME properties are 
important to find the pharmacodynamics of selected molecules that 
could be used as drug.
Molecular docking
Finally, the 12 lichen compounds which are exhibiting drug-likeness 
were taken to account for docking studies using the Glide module. The 
interactions of selected proteins and lichen compounds were observed 
using PyMOL software [16,17].
© 2021 The Authors. Published by Innovare Academic Sciences Pvt Ltd. This is an open access article under the CC BY license (http://creativecommons.org/
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Table 1: Interactions of selected lichen compounds with SARS‑CoV‑2 target proteins
Ligand (PubChem ID) G-score (kcal/mol) Bond length (Å) No. of hydrogen bonds Interacting residues
Main protease (PDB ID: 6lu7)
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Fig. 1: (a) Interaction of fallacinol with spike protein (6M0J). (b) Interaction of 4-O-Demethylbarbatic acid with main protease (6lu7)
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Table 1: (Continued)
Ligand (PubChem ID) G-score (kcal/mol) Bond length (Å) No. of hydrogen bonds Interacting residues
Spike protein (PDB ID: 6M0J)
































































































































Asian J Pharm Clin Res, Vol 14, Issue 12, 2021, 100-104
 Prabhu et al.




























SARS-CoV: Severe acute respiratory syndrome coronavirus
Table 1: (Continued)
Ligand (PubChem ID) G-score (kcal/mol) Bond length (Å) No. of hydrogen bonds Interacting residues
Pannaric acid, diploschistic acid, lecanoric acid, and haematommone 
have shown good binding affinity of −11.78 kcal/mol, −11.74 kcal/mol, 
−11.58 kcal/mol, and −11.37 kcal/mol, respectively, with spike protein, 
each formed 7, 7, 5, and 5 hydrogen bonds. The above compounds have 
shown ADME properties and drug-likeness was also noteworthy.
Note: Split pea green color represents the amino acid residues of the 
protein and deep salmon red color indicates the ligands.
DISCUSSION
The in silico method such as docking is an effective strategy and widely 
used method for understanding the molecular aspects of proteins 
and protein-ligand interactions in the drug discovery process [18]. 
Identification of effective drugs for treating COVID-19 patients is an 
urgent need of global pandemic COVID-19. The various discoveries 
made through computational studies possess significance in regard the 
discovery of a potential drug, as the success of the derived molecules 
is obvious. The present study indicates the efficient binding of lichen 
compounds such as fallacinol and 4-O-Demethylbarbatic acid with the 
active amino acid residues of the main protease and spike protein of 
SARS-CoV-2 with the least G-Score.
CONCLUSION
This study finding suggested that the use of naturally occurring lichen 
substances could serve as efficient therapeutics for the treatment of 
COVID-19. Through this structural bioinformatics approach, some of 
the lichen compounds are potential against the protein targets (main 
protease and spike protein) of SARS-CoV-2.
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Fig. 2: (a) Chemical structure if fallacinol (b) chemical structure 
4-O-Demethylbarbatic acid
RESULTS
Molecular docking studies of lichen secondary metabolites 
(14 compounds) were carried out with SARS-CoV-2 proteins. The 
interactions of lichen metabolites with main protease and spike protein 
of SARS-CoV-2 tabulated with G-Score, number of hydrogen bonds, 
bond length, and the interacting residues (Table 1). The amino acid 
residues of the proteins (6lu7 and 6M0J) were determined by LIGSITE 
tool. The residues are Lys-5, Lys-137, Gln-110, Gln-127, Glu-288, 
Glu-290, Arg-4, Asp-153, Lys-102, Asp-289 and Asn-394, Asp-382, 
Tyr-127,Tyr-515, Arg-273, Arg-514, Arg-518, Glu-375 Glu-398, Glu-
402, Glu-406, His-345, His-378, His-505, Ala-348, Gln-442, and Ser-409. 
Among the lichen compounds, fallacinol and 4-O-Demethylbarbatic acid 
exhibited the least G score (−11.83 kcal/mol and −11.67 kcal/mol) against 
spike protein and main protease respectively with 8 and 5 hydrogen 
bonds. The residues Asn-394, Asp-382, Tyr-515, Arg-514, and Glu-398 of 
spike protein and Lys-137, Lys-5, Gln-127, and Arg-4 of the main protease 
are predicted as active sites and had interactions with above said ligands, 
respectively. The bond lengths were observed as 2.6, 2.1, 2.6, 2.2, 2.1, 1.9, 
3.1 Å and 1.8, 2.1, 1.7, 1.8, 1.9 Å with respect to the above residues of both 
proteins. The interaction of fallacinol and 4-O-Demethylbarbatic acid 
with SARS-CoV-2  proteins  shown in Fig. 1 and 2D structures of fallacinol 
and 4-O-Demethylbarbatic acid are shown in Fig. 2.
The compounds emodin and diploschistic acid were also showed 
significant binding affinity (−11.56 kcal/mol and −11.36 kcal/mol) 
against the main protease with 4 and 3 hydrogen bonds, respectively. 
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